Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Recent executive changes in the industry include C-suite changes at Radius Health and Sorrento Therapeutics. Meanwhile, new directors were appointed at Amarin Corp and Suzhou Zelgen Biopharmaceuticals, among others.
In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.
Recent executive changes in the industry include C-suite changes at Zentalis Pharmaceuticals and Morphic Holding. Meanwhile, new directors were appointed at SpineThera and Avenue Therapeutics, among others.
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
Recent executive changes in the industry include C-suite changes at Legend Biotech and Seagen. Meanwhile, new directors were appointed at Alligator Bioscience and Kintor Pharmaceutical, among others.
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
The company will shift development of INO-4800 to a booster strategy. It also announced it must conduct additional studies of the cervical dysplasia drug VGX-3100 after an FDA meeting.
Lecanemab is now filed for accelerated approval with the US FDA, but the wait for a Phase III readout could impact the hunt for Biogen’s next CEO.
Pharma veteran Paul Stoffels, the new CEO of Galapagos, is not thinking about using the Belgian biotech’s cash pile to buy Phase III drugs but is open to licensing deals with US firms who have drugs approved at home and are looking for a European partner.
Recent executive changes in the industry include C-suite changes at Saniona AB and Denali Therapeutics. Meanwhile, new directors were appointed at Biohaven and Esperion Therapeutics.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.